TCTR20210913001
Completed
Not Applicable
Immunogenicity and safety of heterologous and homologous prime-boost schedules with an adenoviral vectored and inactivated SARS-CoV-2 (COVID-19) vaccines
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- The Royal College of Physicians of Thailand
- Enrollment
- 400
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Thai nationality
- •2\. Received one dose of CoronaVac 3\-4 weeks prior or one dose of ChAdOx1\-S nCoV\-19 4\-12 weeks prior
Exclusion Criteria
- •1\. Prior COVID\-19 infection
- •2\. Allergic to vaccine or vaccine component
- •3\. Receiving immunosuppressants, immunoglobulin or blood components within 3 months
- •4\. Anatomical or functional asplenia
- •5\. Drug abuse or alcoholism
- •6\. Autoimmune or immunodeficiency diseases
- •7\. Pregnancy or lactation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
Completed
Not Applicable
Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort TrialTCTR20220516002Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand130
Completed
Not Applicable
Safety of Malaria vaccines in Gambian infantsMalariaPaediatricsPACTR201401000363170niversity of Oxford36
Completed
Not Applicable
Safety of Malaria vaccines in Gambian childreMalariaPaediatricsPACTR201204000362870niversity of Oxford36
Unknown
Not Applicable
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52